Novo Nordisk is trading 3.07% down at $47.16 after Eli Lilly launched its competing Foundayo oral weight-loss treatment in the UK on August 24, intensifying pressure in the obesity-pill market.
- Shares gained 3.71% to $48.66 on August 25.
- Broader U.S. indexes remain nearly flat.
- Recent coverage says Novo’s Wegovy pill faces increasing competition despite retaining a reported 90% oral GLP-1 share.